Drug intelligence / Profile preview

CS08399

Development stage: Phase 1
Lead developer: Akeso
Modality: Small Molecules
Administration: Oral

Overview

CS08399 is a brain-penetrant small molecule inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) being developed by Chipscreen Biosciences. PRMT5 is an epigenetic enzyme that catalyzes the symmetric dimethylation of arginine residues on histone and non-histone proteins, playing a crucial role in gene expression regulation and cellular signaling. By crossing the blood-brain barrier, CS08399 is designed to target PRMT5 within the central nervous system, offering a potential therapeutic approach for neurodegenerative diseases where PRMT5-mediated pathways are implicated in disease progression. It is currently in the preclinical research stage.

Targets

PRMT5 (Protein arginine N-methyltransferase 5)

Beyond the preview

Go deeper on CS08399.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS08399.

Explore the full profile